Gene Signal In Talks For A Partner For Eye Disease Drug

Gene Signal In Talks For A Partner For Eye Disease Drug

Gene Signal In Talks For A Partner For Eye Disease Drug
Biotechnology News

By Caroline Copley ZURICH (Reuters) - Gene Signal is in talks with potential partners to help develop its new treatment for a leading cause of blindness in the elderly, the biotech firm's chief executive said on Tuesday. Privately-held Gene Signal is looking to muscle in on the lucrative market for treating wet age-related macular degeneration (AMD) currently dominated by Roche's Lucentis and Regeneron's Eylea. Unlike Lucentis and Eylea, which must be injected into the eye, Gene Signal's aganirsen is administered topically as an eye drop or an emulsion, making it a less cumbersome and potentially more convenient treatment. Chief Executive Eric Viaud, who co-founded Gene Signal in 2000, said the company was already in discussions about possible partnerships to develop the drug in AMD.

Source